Scholar Rock Holding (SRRK) Long-Term Debt Issuances (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Long-Term Debt Issuances of $196.7 million for Q1 2026, up 697.35% year-over-year from $24.7 million in Q1 2025, and up 676.67% quarter-over-quarter from $25.3 million in Q3 2025.
Powered by 
Analysis
Scholar Rock Holding (SRRK) Long-Term Debt Issuances (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Long-Term Debt Issuances history runs 6 years deep, the most recent figure standing at $196.7 million for Q1 2026.
- In Q1 2026, Long-Term Debt Issuances rose 697.35% year-over-year to $196.7 million; the TTM figure through Mar 2026 stood at $222.0 million (up 346.99% YoY), while the FY2025 annual figure was $50.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q1 2026 stood at $196.7 million, up from $25.3 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $196.7 million in Q1 2026, with the low at $1000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Scholar Rock Holding | 7.19 Bn | 7.19 Bn | - | 97.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 97.73 Mn |
| Mar 31, 2026 | 196.68 Mn |
| Sep 30, 2025 | 25.32 Mn |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 24.67 Mn |
| Dec 31, 2021 | 25.00 Mn |
| Jun 30, 2019 | 198,000.00 |
| Mar 31, 2019 | 167,000.00 |
| Dec 31, 2018 | 167,000.00 |
| Sep 30, 2018 | 167,000.00 |
| Jun 30, 2018 | 166,000.00 |
| Mar 31, 2018 | 167,000.00 |
| Sep 30, 2017 | 167,000.00 |